Aims: To detect non-viral mRNA in human plasma that has been frozen for three years using a new protocol.

Methods: Plasma from 15 patients with colorectal cancer and 10 normal subjects was separated and frozen with Trizol at −80°C for three years. As a control measure, plasma from 10 of the 15 patients was separated using the same protocol but no Trizol during storage. After three years, all samples were extracted using Trizol and RNeasy before the reverse transcriptase polymerase chain reaction was performed to detect non-viral β catenin mRNA. In addition, extraction of three plasma samples by Trizol or RNeasy independently was carried out for comparison.

Results: β Catenin mRNA was detected in all 15 patient plasma samples and only one of the 10 normal subjects. In contrast, no β catenin mRNA was found in the control and patient samples that were independently extracted by Trizol and RNeasy kit.

Conclusions: This new protocol is a reliable method for extracting non-viral mRNA from the plasma of patients with cancer after longterm storage for three years. Extractions using Trizol and RNeasy kits independently could not isolate mRNA with sufficient quantity and quality for detection.

Methods

Our study was approved by the local institutional committee and informed consent was obtained from 15 patients with colorectal cancer and 10 normal subjects in January 1999. For each subject, 6 ml of blood was collected in EDTA coated polypropylene tubes (2 ml each). The tubes were centrifuged at 3838 g for eight minutes at 4°C, followed by careful separation of 1 ml plasma from each tube into a ribonuclease free Eppendorf tube with 1 ml Trizol, and stored at −80°C for three years. As a control measure, blood was also collected from 10 of the above patients with colorectal cancer and their plasma was separated and stored at −80°C for three years without Trizol.

After storage for three years, mRNA was extracted using Trizol (Life Technologies, Carlsbad, California, USA), and further purified with the RNeasy kit (Qiagen, Hilden, Germany). In brief, a 2 ml plasma sample with Trizol was mixed with 0.4 ml chloroform before centrifugation. The aqueous phase was collected for mRNA extraction using the RNeasy kit. β Catenin mRNA was detected after treatment with DNase I (Life Technologies) and Omniscript reverse transcriptase (Qiagen), according to the manufacturers’ instructions, and polymerase chain reaction (PCR) assay with a set of intron spanning primers (table 1; primer set 1). To prove the amplifiable nature of those specimens, plasma samples with negative results were subjected to β actin mRNA detection by another set of intron spanning primers (table 1; primer set 2). Aliquots of 6 µl cDNA were used for each PCR reaction, which was carried out using reagents supplied in the GeneAmp DNA amplification kit using AmpliTaq Gold as the polymerase (Perkin-Elmer, Foster City, California, USA). The PCR parameters were as follows: an initial denaturation at 95°C for 10 minutes, followed by 40 cycles of 94°C for 75 seconds, 59°C for 90 seconds, and 72°C for 90 seconds, with a final extension step of 72°C for 10 minutes. PCR products were separated by electrophoresis using a 1.5% agarose gel and visualised by ethidium bromide staining. Duplicate samples were performed for each data point.

Abbreviations: PCR, polymerase chain reaction

Traditional methods in cancer detection such as colono-scopy and sigmoidoscopy are highly specific and sensitive tests but they are invasive and limited by high costs and demanding expertise.1 Recent reports have indicated that plasma can be an important source of genomic DNA or mRNA in patients with cancer.2–4 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23 Preliminary results on plasma can be an important source of genomic DNA or mRNA in patients with cancer.23
In addition, patient samples 1 to 3 that had been stored in Trizol were extracted independently using Trizol reagent or the RNeasy mini kit according to the manufacturers' instructions for comparison. All other steps were the same.

**RESULTS**

All 15 plasma samples from patients with colorectal cancer showed a 250 bp fragment (fig 1) consistent with β-catenin mRNA. To prove that it was derived from mRNA and not DNA, we performed the test on a positive control without DNase I. As expected, it yielded a 250 bp band amplified from mRNA and a 450 bp band amplified from the residual DNA (fig 1). No β-catenin mRNA was detected in the negative (plasma from normal subject) and water controls (fig 1).

Nine of the 10 plasma samples from normal subjects had no β-catenin mRNA (fig 2A). The plasma DNA positive control and the negative control gave the expected results. All samples with negative results were tested for β-actin mRNA and all 10 normal subjects showed visible bands of 230 bp (fig 2B). The plasma DNA positive control and the negative control gave the expected results (fig 2B).

However, β-catenin mRNA was not detected in the 10 control colorectal cancer plasma samples that had not had Trizol present during the three year storage period (fig 3A). In addition, the same batch of samples did not contain β-actin mRNA (fig 3B).

Finally, patient plasma samples 1 to 3 were also extracted independently using either Trizol or the RNeasy kit (fig 4) with the same post-extraction protocols. No β-catenin mRNA could be detected by either method.

**DISCUSSION**

The successful demonstration of plasma β-catenin mRNA in all patients with colorectal cancer and its absence in normal controls clearly attest to the superiority of our protocol for plasma mRNA extraction after freezing at −80°C for three years. Moreover, our findings also indicate that the addition of Trizol during storage is an important factor in the stabilisation of mRNA over such a long period because both β-catenin and β-actin mRNA could not be detected using this extraction protocol when Trizol was not present during the three year storage period.

Our protocol, using centrifugation at 3838 xg for eight minutes, may produce plasma with a rich source of both particle associated and non-particle associated circulating mRNA for detection because cell free plasma requires either a much higher centrifugal force of 99 960 xg for 120 minutes or a filtration step. Therefore, a lower centrifugal force probably produces plasma with more mRNA—Kopreski et al.

---

**Table 1** Sequences of primers used in our study

<table>
<thead>
<tr>
<th>Primer sets</th>
<th>Design</th>
<th>Nucleotide sequence (5' to 3')</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Intron between exon 3 and 4 of β-catenin gene</td>
<td>Sense: TGATTGTGGGAGTTGGACAT</td>
<td>DNA, 450 bp</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antisense: CATTGCACATGTCCATCAAT</td>
<td>cDNA, 250 bp</td>
</tr>
<tr>
<td>2</td>
<td>Intron between exon 4 and 5 of β-actin gene</td>
<td>Sense: AAATCGTGCGTGACATTAAGG</td>
<td>DNA, 324 bp</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antisense: ATGATGGGATTGAGGTTAGT</td>
<td>cDNA, 230 bp</td>
</tr>
</tbody>
</table>

---

**Figure 1** Detection of plasma RNA in patients with colorectal cancer: lanes 1–15, β-catenin mRNA (250 bp) from 15 patients; lane 16, β-catenin mRNA (250 bp) and DNA (450 bp) from a positive control; lane 17, negative control; lane 18, water control; lane M, molecular markers.

**Figure 2** Detection of plasma RNA in normal subjects. (A) Lanes 1–10, β-catenin mRNA from 10 normal subjects; lane 11, β-catenin DNA from a positive control; lane 12, negative control; lane M, molecular markers. (B) Lanes 1–10, β-actin mRNA from 10 normal subjects; lane 11, β-actin mRNA from a positive control; lane 12, water control; lane M, molecular markers.

**Figure 3** Lack of detection of RNA in plasma from patients with colorectal cancer stored for three years without Trizol: (A) lanes 1–10, β-catenin mRNA from 10 patients; (B) lanes 1–10, β-actin mRNA from 10 patients.

**Figure 4** Detection of plasma RNA in patients 1–3 with colorectal cancer using both methods independently: lanes 1–3, β-catenin mRNA extracted by Trizol; lanes 4–6, β-catenin mRNA extracted by RNeasy kit; lane M, molecular markers.
Take home messages

- We have devised a reliable method using a combination of Trizol and RNeasy kits for extracting non-viral mRNA from the plasma of patients with cancer after long-term storage for three years.
- Extractions using Trizol and RNeasy kits independently could not isolate mRNA with sufficient quantity and quality for detection.
- The incidental discovery of β-catenin mRNA in the plasma of patients with colorectal cancer but not in most healthy subjects requires further investigation.

and Silva et al. used centrifugal forces as low 830 g and 1000 g for 10 minutes in their mRNA extraction protocols, respectively.

“Our findings indicate that the addition of Trizol during storage is an important factor in the stabilisation of mRNA over such a long period.”

A previous study where mRNA was extracted from 3 ml plasma samples using RNeasy kit and nested PCR had positive rates of only 60% for mammaglobin and 49% for cytokeratin 19. Our new protocol increases the percentage of positivity and has the advantage that mRNA can be extracted from only 2 ml of plasma and that it saves time in the first centrifugation step after the addition of one volume of 70% alcohol using the RNeasy kit. In addition, routine rather than nested PCR can be used, which is also an advantage because this last technique is very sensitive but increases the risk of false positivity as a result of contamination. In contrast, we showed that the quantity and quality of extracted mRNA were inadequate for cDNA synthesis when either the Trizol or the RNeasy extraction method was used independently. This might be because although Trizol extracts sufficient mRNA for further processing, the quality is poor, as is the case with many non-specific products. In practice, the Trizol method makes it difficult to obtain a visible and purified mRNA precipitate from plasma for further processing, whereas RNeasy extraction has the disadvantages that the mini spin column has a maximum binding capacity of only 100 μg mRNA and its lytic buffer might form precipitates with plasma that may clot the column, which can greatly reduce the amount of mRNA isolated.

The discovery of β-catenin mRNA in the plasma of patients with colorectal cancer but not in most of the healthy subjects is an incidental finding by us and requires further investigation. The only normal subject in whom plasma β-catenin mRNA was detected had severe rectal inflammation five years previously and was still suffering from diarrhoea. Selected β-catenin cDNA products (seven of 15 colorectal cancer samples) were confirmed by sequencing (data not shown).

In conclusion, this new protocol should be useful because it is the first to isolate high quality non-viral mRNA from patients’ plasma that had been frozen for three years.

ACKNOWLEDGEMENTS

We thank Dr JKC Chan for valuable discussions. This work was supported by Io Hung Chiu Medical Foundation Research Grant.

Authors’ affiliations

S C C Wong, E S F Lo, Department of Pathology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China

M T Cheung, Department of Surgery, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China

Correspondence to: Dr S C C Wong, Department of Pathology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China; cesar01@netvigator.com

Accepted 27 February 2004

REFERENCES


An optimised protocol for the extraction of non-viral mRNA from human plasma frozen for three years

S C C Wong, E S F Lo and M T Cheung

*J Clin Pathol* 2004 57: 766-768
doi: 10.1136/jcp.2003.007880

Updated information and services can be found at:
http://jcp.bmj.com/content/57/7/766

These include:

**References**
This article cites 11 articles, 8 of which you can access for free at:
http://jcp.bmj.com/content/57/7/766#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Colon cancer (231)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/